SCHEMBL1857686

SCHEMBL1857686

O=C(O)C(O)Cc1ccc([N+](=O)[O-])cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.50
KDM6B O15054 1/20 0.50
TSHR P16473 1/20 0.50
MEN1 O00255 1/20 0.50
KMT2A Q03164 1/20 0.50
CYP2C19 P33261 3/20 0.49
CYP1A2 P05177 2/20 0.49
LOXL2 Q9Y4K0 1/20 0.48
TDP1 Q9NUW8 1/20 0.48
CA2 P00918 1/20 0.48
NPC1 O15118 1/20 0.48
TP53 P04637 1/20 0.48
RAB9A P51151 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
ALDH1A1 P00352 2/20 0.47
CES1 P23141 1/20 0.46
ANPEP P15144 1/20 0.45
ERAP2 Q6P179 1/20 0.45
ERAP1 Q9NZ08 1/20 0.45
IDO1 P14902 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4365310 1.00 LMNA (0.50) LMNAKDM6BTSHRMEN1KMT2A
SCHEMBL1857683 1.00 LMNA (0.50) LMNAKDM6BTSHRMEN1KMT2A
SCHEMBL8953727 1.00 LMNA (0.50) LMNAKDM6BTSHRMEN1KMT2A
SCHEMBL3091161 0.85 TSHR (0.53) LMNATSHRMEN1KMT2ACYP2C19
SCHEMBL1666842 0.84 MEN1 (0.52) LMNATSHRMEN1KMT2ACYP2C19
SCHEMBL19369766 0.84 MAPK1 (0.50) LMNATSHRMEN1KMT2ACYP2C19
SCHEMBL4592273 0.84 MAPK1 (0.50) LMNATSHRMEN1KMT2ACYP2C19
SCHEMBL8102675 0.84 GSK3B (0.53) LMNATSHRMEN1KMT2ACYP2C19
SCHEMBL10436410 0.84 CPA1 (0.57) LMNATSHRMEN1KMT2ACYP2C19
SCHEMBL2561037 0.83 TSHR (0.56) LMNATSHRMEN1KMT2ACYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1291417-B1 NOVEL (R)-2-HYDROXY-3-PHENYLPROPIONATE (D-PHENYLLACTATE) DEHYDROGENASE AND GENE ENCODING THE SAME MEIJI SEIKA KAISHA (JP) 2007-02-21 EP claimed
CN-112384511-B Endoparasite depsipeptides 硕腾服务有限责任公司 2024-01-30 CN disclosed
US-11786575-B2 Endoparasitic depsipeptides ZOETIS SERVICES LLC (US) 2023-10-17 US disclosed
CN-115851525-B Chloramphenicol degrading bacterium, chloramphenicol dehydrogenase, encoding gene and application thereof 安徽农业大学 2023-10-13 CN disclosed
US-11771738-B2 Endoparasitic depsipeptides ZOETIS SERVICES LLC (US) 2023-10-03 US disclosed
CN-111741956-B Antiparasitic depsipeptides 硕腾服务有限责任公司 2023-07-07 CN disclosed
CN-116322683-A Compounds as C5AR inhibitors 科越医药(苏州)有限公司 2023-06-23 CN disclosed
CN-116120240-A FXIa inhibitor compound, preparation method and medical application thereof 深圳信立泰药业股份有限公司 2023-05-16 CN disclosed
CN-115851525-A Chloramphenicol degrading bacteria, chloramphenicol dehydrogenase, encoding gene and application thereof 安徽农业大学 2023-03-28 CN disclosed
CN-114206854-B FXIa inhibitor and preparation method and medical application thereof 深圳信立泰药业股份有限公司 2023-02-24 CN disclosed
EP-0736035-A1 PRETARGETING METHODS AND COMPOUNDS NEORX CORPORATION (US) 1996-10-09 EP disclosed
US-5541287-A DIAGNOSIS USING CYCLIC TRIPEPTIDES WITH NITROBENZYL 1,4,7,10-TETRAAZACYCLODODECANE-N,N*,N**,N***TETRAACETIC ACID BIOTIN CONJUGATE FORMED BY ALKYLATION AND MULTISTAGE PROCESS NEORX CORPORATION (US) 1996-07-30 US disclosed
EP-0718293-A1 CYCLODEPSIPEPTIDE COMPOUND FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1996-06-26 EP disclosed
WO-1995015335-A2 PRETARGETING METHODS AND COMPOUNDS NEORX CORPORATION (US) 1995-06-08 WO disclosed
EP-0634408-A1 DEPSIPEPTIDE DERIVATIVE, PRODUCTION THEREOF AND USE THEREOF FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1995-01-18 EP disclosed
CN-1080932-A Depsipeptide derivative and manufacture method thereof and purposes FUJISAWA PHARMACEUTICAL CO (JP) 1994-01-19 CN disclosed
US-5225431-A Treatment of migraine BURROUGHS WELLCOME CO. (US) 1993-07-06 US disclosed
EP-0313397-B1 THERAPEUTIC HETEROCYCLIC COMPOUNDS THE WELLCOME FOUNDATION LIMITED (GB) 1993-06-02 EP disclosed
CN-1035113-A The heterogeneous ring compound that is used for the treatment of WELLCOME FOUND (GB) 1989-08-30 CN disclosed
EP-0313397-A1 Therapeutic heterocyclic compounds THE WELLCOME FOUNDATION LIMITED (GB) 1989-04-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11786575-B2 Endoparasitic depsipeptides VIP, PREP, NGLY1 LMNA 1682/4885KDM6B 4031/4885TSHR 1622/4885
US-11771738-B2 Endoparasitic depsipeptides VIP, PREP, VIPR1 LMNA 2449/4885KDM6B 4186/4885TSHR 1643/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.